123 related articles for article (PubMed ID: 1638529)
1. Inhibition of hematopoietic tumor growth by combined treatment with deferoxamine and an IgG monoclonal antibody against the transferrin receptor: evidence for a threshold model of iron deprivation toxicity.
Kemp JD; Thorson JA; Stewart BC; Naumann PW
Cancer Res; 1992 Aug; 52(15):4144-8. PubMed ID: 1638529
[TBL] [Abstract][Full Text] [Related]
2. Inhibition of lymphoma growth in vivo by combined treatment with hydroxyethyl starch deferoxamine conjugate and IgG monoclonal antibodies against the transferrin receptor.
Kemp JD; Cardillo T; Stewart BC; Kehrberg E; Weiner G; Hedlund B; Naumann PW
Cancer Res; 1995 Sep; 55(17):3817-24. PubMed ID: 7641199
[TBL] [Abstract][Full Text] [Related]
3. Synergistic inhibition of lymphoid tumor growth in vitro by combined treatment with the iron chelator deferoxamine and an immunoglobulin G monoclonal antibody against the transferrin receptor.
Kemp JD; Smith KM; Kanner LJ; Gomez F; Thorson JA; Naumann PW
Blood; 1990 Sep; 76(5):991-5. PubMed ID: 2393721
[TBL] [Abstract][Full Text] [Related]
4. Inhibition of growth of human breast carcinoma cells by an antisense oligonucleotide targeted to the transferrin receptor gene.
Yang DC; Jiang XP; Elliott RL; Head JF
Anticancer Res; 2001; 21(3B):1777-87. PubMed ID: 11497259
[TBL] [Abstract][Full Text] [Related]
5. Combinations of anti-transferrin receptor monoclonal antibodies inhibit human tumor cell growth in vitro and in vivo: evidence for synergistic antiproliferative effects.
White S; Taetle R; Seligman PA; Rutherford M; Trowbridge IS
Cancer Res; 1990 Oct; 50(19):6295-301. PubMed ID: 2400993
[TBL] [Abstract][Full Text] [Related]
6. Modulation of transferrin receptor expression by inhibitors of nucleic acid synthesis.
Hedley D; Rugg C; Musgrove E; Taylor I
J Cell Physiol; 1985 Jul; 124(1):61-6. PubMed ID: 2413049
[TBL] [Abstract][Full Text] [Related]
7. The iron metabolism of the human neuroblastoma cell: lack of relationship between the efficacy of iron chelation and the inhibition of DNA synthesis.
Richardson DR; Ponka P
J Lab Clin Med; 1994 Nov; 124(5):660-71. PubMed ID: 7964124
[TBL] [Abstract][Full Text] [Related]
8. Effects of all-trans retinoic acid and antireceptor antibodies on growth and programmed cell death of human myeloma cells.
Taetle R; Dos Santos B; Akamatsu K; Koishihara Y; Ohsugi Y
Clin Cancer Res; 1996 Feb; 2(2):253-9. PubMed ID: 9816167
[TBL] [Abstract][Full Text] [Related]
9. Role of iron in T cell activation: TH1 clones differ from TH2 clones in their sensitivity to inhibition of DNA synthesis caused by IgG Mabs against the transferrin receptor and the iron chelator deferoxamine.
Thorson JA; Smith KM; Gomez F; Naumann PW; Kemp JD
Cell Immunol; 1991 Apr; 134(1):126-37. PubMed ID: 1826464
[TBL] [Abstract][Full Text] [Related]
10. Neuroblastoma sensitivity to growth inhibition by deferrioxamine: evidence for a block in G1 phase of the cell cycle.
Brodie C; Siriwardana G; Lucas J; Schleicher R; Terada N; Szepesi A; Gelfand E; Seligman P
Cancer Res; 1993 Sep; 53(17):3968-75. PubMed ID: 8358725
[TBL] [Abstract][Full Text] [Related]
11. Induction of apoptosis by iron depletion in the human breast cancer MCF-7 cell line and the 13762NF rat mammary adenocarcinoma in vivo.
Jiang XP; Wang F; Yang DC; Elliott RL; Head JF
Anticancer Res; 2002; 22(5):2685-92. PubMed ID: 12529982
[TBL] [Abstract][Full Text] [Related]
12. Binding characteristics and antitumor properties of 1A10 bispecific antibody recognizing gp40 and human transferrin receptor.
Amoroso AR; Clark JI; Litwin S; Hsieh-Ma S; Shi T; Alpaugh RK; Adams GP; Wolf EJ; Ring DB; Weiner LM
Cancer Res; 1996 Jan; 56(1):113-20. PubMed ID: 8548750
[TBL] [Abstract][Full Text] [Related]
13. Synergistic inhibition of T-lymphoblastic leukemic CCRF-CEM cell growth by gallium and recombinant human alpha-interferon through action on cellular iron uptake.
Chitambar CR; Wereley JP; Riaz-ul-Haq
Cancer Res; 1994 Jun; 54(12):3224-8. PubMed ID: 8205543
[TBL] [Abstract][Full Text] [Related]
14. Structure and function of transferrin receptors and their relationship to cell growth.
Trowbridge IS; Shackelford DA
Biochem Soc Symp; 1986; 51():117-29. PubMed ID: 3545211
[TBL] [Abstract][Full Text] [Related]
15. Mechanisms of growth inhibition by anti-transferrin receptor monoclonal antibodies.
Taetle R; Castagnola J; Mendelsohn J
Cancer Res; 1986 Apr; 46(4 Pt 1):1759-63. PubMed ID: 3004704
[TBL] [Abstract][Full Text] [Related]
16. Effects of transferrin-indium on cellular proliferation of a human leukemia cell line.
Moran PL; Seligman PA
Cancer Res; 1989 Aug; 49(15):4237-41. PubMed ID: 2743310
[TBL] [Abstract][Full Text] [Related]
17. Effects of monoclonal antibodies that block transferrin receptor function on the in vivo growth of a syngeneic murine leukemia.
Sauvage CA; Mendelsohn JC; Lesley JF; Trowbridge IS
Cancer Res; 1987 Feb; 47(3):747-53. PubMed ID: 3802079
[TBL] [Abstract][Full Text] [Related]
18. Effects of monoclonal anti-transferrin receptor antibodies on in vitro growth of human solid tumor cells.
Taetle R; Honeysett JM
Cancer Res; 1987 Apr; 47(8):2040-4. PubMed ID: 3828993
[TBL] [Abstract][Full Text] [Related]
19. Role of the transferrin receptor in lymphocyte growth: a rat IgG monoclonal antibody against the murine transferrin receptor produces highly selective inhibition of T and B cell activation protocols.
Kemp JD; Thorson JA; McAlmont TH; Horowitz M; Cowdery JS; Ballas ZK
J Immunol; 1987 Apr; 138(8):2422-6. PubMed ID: 2951439
[TBL] [Abstract][Full Text] [Related]
20. Effects of anti-transferrin receptor antibodies on the growth of neoplastic cells.
Kemp JD; Smith KM; Mayer JM; Gomez F; Thorson JA; Naumann PW
Pathobiology; 1992; 60(1):27-32. PubMed ID: 1543548
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
